Successful financial year 2024 for HARTMANN - Company aims to further improve earnings in 2025

Heidenheim, 20 March 2025. HARTMANN successfully continued its Transformation Program last year. The program contributed to significant improvements in earnings of over EUR 50 million, primarily through the launch of new products and structural cost measures, despite persistently challenging market conditions.

In 2024, the HARTMANN GROUP generated sales revenues of EUR 2,407.9 million, achieving organic sales growth of 2.6% compared to 2023. Revenue growth was particularly strong in strategically important segments, where new products helped drive sales and gain market share.

Adjusted EBITDA rose to EUR 261.4 million, an increase of nearly EUR 60 million or 29% over the previous year. This marks the highest earnings in the Company’s history, excluding 2020, which was significantly influenced by pandemic-related effects. The adjusted EBITDA margin rose by more than 2 percentage points to 10.9%. The positive earnings performance is primarily attributable to the Transformation Program measures implemented in the 2024 financial year.

The Wound Care segment generated sales of EUR 608.9 million (organic growth: 4.4%). Growth was driven by the area of advanced wound care, in particular silicone-based superabsorbent wound dressings. In this segment, market share was gained in the core markets.

The Incontinence Management segment generated sales of EUR 769.9 million (organic growth: 1.6%). Incontinence pants once again proved to be a particularly strong-selling product range in the reporting year.

The Infection Management segment recorded sales of EUR 518.9 million (organic growth: 0.6%). Market share was gained in surface and hand disinfection. The trading business with protective equipment declined.

Sales in the Complementary Group Divisions segment amounted to EUR 510.2 million (organic growth: 4.0%). This growth is due in particular to the positive development of the CMC Group, but KOB and Kneipp also contributed to organic growth.

HARTMANN is adhering to its long-standing principle of a dividend policy based on continuity and proposing a dividend of EUR 8 per share.

Britta Fünfstück, CEO of the HARTMANN GROUP: “We will continue to focus on our Transformation Program. HARTMANN’s strategy remains dedicated to securing leading market positions and enhancing the Group’s profitability, ensuring we can sustain long-term competitiveness through continued investment.”

For the financial year 2025, HARTMANN expects moderate organic sales growth and an adjusted EBITDA in the range of EUR 260 to 300 million.

The annual report and annual financial statements for the 2024 financial year can be found at https://corporate.hartmann.info/en/investor-relations.

The HARTMANN GROUP is one of the leading European providers of professional medical and care products and associated services. Every day, healthcare professionals and patients rely on HARTMANN brands in the segments of Incontinence Management (e.g. MoliCare®), Wound Care (e.g. Zetuvit®, Cosmopor®) and Infection Management (e.g. Sterillium®). This is expressed in our brand promise of “Helps. Cares. Protects.” Founded in 1818, the Company sells its products and solutions in 130 countries around the world.

To learn more about the HARTMANN GROUP, visit www.corporate.hartmann.info.